T. Andrew Lister

Q: What Schools Are Affiliated With T. Andrew Lister

T. Andrew Lister is affiliated with the following schools: Institute of Cancer Research, University of Erlangen–Nuremberg, University of Oxford, University College London, Queen Mary University of London, University of Bologna, University of Münster

T. Andrew Lister's AcademicInfluence.com Rankings

T. Andrew Lister

Engineering

#4011

World Rank

#5164

Historical Rank

Biomedical Engineering

#224

World Rank

#231

Historical Rank

engineering Degrees

T. Andrew Lister

Philosophy

#5733

World Rank

#8620

Historical Rank

Logic

#2956

World Rank

#4040

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

T. Andrew Lister's Degrees

PhD Biomedical Engineering University of California, Berkeley
Doctorate Medicine University of California, San Francisco

Why Is T. Andrew Lister Influential?

(Suggest an Edit or Addition)

(See a Problem?)

T. Andrew Lister's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A predictive model for aggressive non-Hodgkin's lymphoma. (1993) (4400)
Revised response criteria for malignant lymphoma. (2007) (4137)
The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. (1999) (3234)
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. (1999) (3170)
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. (2014) (3134)
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. (2003) (2541)
A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project (1997) (1664)
Stromal gene signatures in large-B-cell lymphomas. (2008) (1611)
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. (1989) (1526)
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. (1999) (1331)
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. (2001) (576)
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. (1994) (559)
The human type‐C retrovirus, HTLV, in blacks from the Caribbean region, and relationship to adult T‐cell leukemia/lymphoma (1982) (546)
Antisera to acute lymphoblastic leukemia cells. (1975) (490)
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. (2000) (472)
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. (2000) (453)
Follicular lymphoma: prognostic factors for response and survival. (1986) (439)
The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 (2000) (404)
Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment (1994) (380)
The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. (2000) (346)
Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. (1995) (341)
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. (2005) (340)
Characterization of Cells with a High Aldehyde Dehydrogenase Activity from Cord Blood and Acute Myeloid Leukemia Samples (2005) (324)
The prognostic value of Ki67 immunostaining in non‐Hodgkin's lymphoma (1988) (301)
Mutation of CEBPA in familial acute myeloid leukemia. (2004) (298)
Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. (2005) (291)
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. (2003) (281)
Failure to preserve fertility in patients with Hodgkin's disease (2004) (255)
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. (2006) (247)
Use of leucocyte‐poor blood components and HLA‐matched‐platelet donors to prevent HLA alloimmunization (1986) (216)
Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. (2000) (207)
CORRELATION OF TRANSFERRIN RECEPTOR EXPRESSION WITH HISTOLOGICAL CLASS AND OUTCOME IN NON-HODGKIN LYMPHOMA (1983) (181)
Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. (1995) (179)
Relative Importance of Immune and Non‐Immune Causes of Platelet Refractoriness (1994) (177)
Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. (1983) (177)
Immunotherapy for Acute Myelogenous Leukaemia (1973) (177)
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. (2011) (175)
Central nervous system toxicity of interferon. (1983) (174)
Histological transformation of non‐hodgkin's lymphoma. A prospective study (1979) (173)
Meta-analysis to evaluate the role of interferon in follicular lymphoma. (2005) (171)
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. (2006) (170)
Diagnosis of acute promyelocytic leukaemia by RT‐PCR: detection of PML‐RARA and RARA‐PML fusion transcripts (1992) (165)
Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. (1999) (165)
Terminal Transferase Enzyme Assay and Immunological Membrane Markers in the Diagnosis of Leukaemia: a Multiparameter Analysis of 300 Cases (1980) (154)
Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. (1978) (154)
The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. (1991) (150)
Emotional support for cancer patients: what do patients really want? (1996) (149)
Lymphoma classification--the gap between biology and clinical management is closing. (1996) (148)
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. (2006) (147)
Blast Crisis of Chronic Myeloid Leukaemia (CML): II. CELL SURFACE MARKER ANALYSIS OF ‘LYMPHOID’AND MYELOID CASES (1976) (146)
MVPP chemotherapy regimen for advanced Hodgkin's disease (1978) (145)
Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. (2001) (144)
Role of image-guided core-needle biopsy in the management of patients with lymphoma. (1996) (143)
Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. (1983) (143)
Relation of “lymphoid” phenotype and response to chemotherapy incorporating vincristine‐prednisolone in the acute phase of Ph1 positive leukemia (1979) (139)
Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy. (1982) (137)
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. (2012) (131)
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. (2001) (130)
Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project. (1997) (130)
Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. (2001) (128)
Treatment of Hodgkin lymphoma: a 50-year perspective. (2014) (127)
Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. (1993) (127)
Prognosis of patients receiving intensive care for lifethreatening medical complications of haematological malignancy (1988) (126)
Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. (1994) (124)
Expression of human T and B lymphocyte cell-surface markers on leukaemic cells. (1974) (122)
Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. (2008) (122)
Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease (2008) (120)
A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. (2006) (119)
Combination chemotherapy for acute lymphoblastic leukaemia in adults. (1978) (118)
Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2 (2003) (117)
A UK multicentre phase II study of rituximab (chimaeric anti‐CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response (2000) (115)
Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. (2000) (115)
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. (2007) (111)
A new member of the proprotein convertase gene family (LPC) is located at a chromosome translocation breakpoint in lymphomas. (1996) (105)
FATAL GRAFT-VERSUS-HOST DISEASE FOLLOWING TRANSFUSION OF GRANULOCYTES FROM NORMAL DONORS (1976) (103)
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. (2004) (101)
Fludarabine phosphate for the treatment of low grade lymphoid malignancy. (1991) (100)
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti‐CD20): a retrospective cohort analysis (2001) (99)
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. (1985) (97)
Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. (2000) (97)
Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia (1987) (96)
Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. (1994) (94)
High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. (1998) (90)
Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. (1977) (87)
Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. (2009) (85)
Acute lymphoblastic leukaemia associated antigen. III ALterations in expression during treatment and in relapse. (1980) (85)
Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma (2007) (84)
The use of real‐time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma (2000) (84)
ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. (2002) (82)
USE OF LEUCOCYTE‐POOR BLOOD COMPONENTS TO PREVENT PRIMARY CYTOMEGALOVIRUS (CMV) INFECTION IN PATIENTS WITH ACUTE LEUKAEMIA (1988) (79)
Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. (1994) (76)
Treatment of acute lymphoblastic leukaemia in adults (1986) (76)
Long term prognosis and quality of life following intensive care for life-threatening complications of haematological malignancy. (1991) (74)
Asymptomatic carotid arterial disease in young patients following neck radiation therapy for Hodgkin lymphoma. (1999) (74)
Immunotherapy for acute myelogenous leukemia. (1975) (74)
Management of follicular lymphoma (1991) (72)
Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. (2003) (71)
Angio-immunoblastic lymphadenopathy: report of ten cases and review of the literature. (1979) (70)
Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. (1999) (69)
Membrane phenotyping: diagnosis, monitoring and classification of acute 'lymphoid' leukaemias. (1977) (69)
Characteristics of Sternberg-Reed, and related cells in Hodgkin's disease: an immunohistological study. (1984) (68)
The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. (1982) (66)
Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. (1991) (65)
Fludarabine in low-grade lymphoma. (1993) (65)
Plasma cell leukemia (PCL): A report on 15 patients (1978) (61)
Heterogeneous sensitivity of human Acute Myeloid Leukemia to ß-catenin down-modulation (2011) (60)
Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. (1993) (59)
The clinical course of follicular lymphoma. (2005) (57)
Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. (2001) (55)
2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. (1993) (54)
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma (2001) (53)
Short-term treatment for acute myelogenous leukaemia. (1982) (52)
Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres. (1988) (52)
Oral anticandidal prophylaxis in patients undergoing chemotherapy for acut- leukemia. (1977) (52)
Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. (1995) (51)
Lymphoma Metastasizing to the Pituitary: An Unusual Presentation of a Treatable Disease (2005) (50)
Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. (1999) (50)
Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care * (2005) (49)
Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study. (2003) (49)
Abnormalities of chromosome 16q in myeloid malignancy: 14 new cases and a review of the literature. (1992) (49)
Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. (2004) (49)
Chromosome 11q23 translocations in both infant and adult acute leukemias are detected by in situ hybridization with a yeast artificial chromosome. (1992) (48)
Management of localized non‐Hodgkin's lymphoma: The experience at St. Bartholomew's hospital 1972–1985 (1989) (48)
Early involvement of the bronchi in patients with malignant lymphoma. (1983) (48)
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. (2000) (48)
Human T‐cell leukaemia virus (HTLV) in the United Kingdom (1984) (47)
Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years (2017) (46)
The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen‐year period (1993) (46)
Chlorambucil and interferon for low grade non-Hodgkin's lymphoma. (1987) (45)
Disappearance of HLA and platelet‐specific antibodies in acute leukaemia patients alloimmunized by multiple transfusions (1987) (45)
Hodgkin's disease in adults: the challenge. (1985) (45)
Chemotherapy of the non‐Hodgkin's lymphomas (1978) (45)
Renal involvement in patients with non‐Hodgkin's lymphoma: Clinical and pathological features in 23 cases (1990) (45)
Detection and significance of bcr-abl mRNA transcripts and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia. (1993) (43)
Frequency of Leukemic Initiating Cells does not depend on the xenotransplantation model used (2011) (42)
A Cross‐matching Procedure for the Selection of Platelet Donors for Alloimmunized Patients (1981) (42)
Intensive therapy for life-threatening medical complications of haematological malignancy (2004) (42)
A clinical and epidemiological study of human leukocyte antigen-DPB alleles in Hodgkin's disease. (1994) (41)
Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome (1990) (39)
Central nervous system toxicity of high-dose cytosine arabinoside. (1985) (39)
Plasma cell leukemia (PCL): A report on 15 patients. (1978) (37)
A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma (2009) (37)
The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. (2006) (36)
Direct sequence analysis of the t(14;18) chromosomal translocation in Hodgkin's disease. (1992) (35)
Acute myeloid leukemia in elderly adults (1990) (35)
The treatment of stage IIIA Hodgkin's disease. (1983) (34)
Chemotherapy and immunotherapy for acute myelogenous leukemia (1980) (34)
Distribution of T-lymphocyte subsets in Hodgkin's disease characterized by monoclonal antibodies. (1982) (34)
Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors (2013) (34)
Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. (2000) (34)
Lymphoplasmacytoid and small cell centrocytic non‐Hodgkin's lymphoma—A retrospective analysis from St Bartholomew's hospital 1972–1986 (1989) (33)
HLA-DP BASED RESISTANCE TO HODGKIN'S DISEASE (1989) (33)
p53 expression in Reed-Sternberg cells of Hodgkin's disease. (1992) (33)
Detection of additional JH/BCL2 translocations in follicular lymphoma. (1991) (32)
Translocation t(6;9)(p23;q34) in acute myeloid leukemia without myelodysplasia or basophilia: two cases and a review of the literature. (1993) (32)
Immunocytoma: a retrospective analysis from St Bartholomew's Hospital-1972 to 1996. (1999) (31)
Combination chemotherapy for haematological relapse in adult acute lymphoblastic leukaemia (ALL) (1978) (31)
Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma (1999) (31)
Life expectancy of young adults with follicular lymphoma. (2015) (31)
APPARENT REMOVAL OF GRAFT‐VERSUS‐LEUKAEMIA EFFECT BY THE USE OF LEUCOCYTE‐POOR BLOOD COMPONENTS IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKAEMIA (1989) (31)
Secondary central nervous system lymphoma: risk factors and prophylaxis. (2005) (29)
Low field strength magnetic resonance imaging of bone marrow in patients with malignant lymphoma. (1988) (29)
The Cotswolds report on the investigation and staging of Hodgkin's disease. (1990) (28)
The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia. (1981) (28)
Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy (1999) (28)
Angio-immunoblastic lymphadenopathy: a clinical, immunological and molecular study. (1987) (28)
Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma. (1999) (28)
Acute lymphoblastic leukaemia in adults: clinicopathological correlations with the French-American-British (FAB) co-operative group classification. (1979) (28)
Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital. (1990) (27)
NEW APPROACHES TO THE TREATMENT OF FOLLICULAR LYMPHOMA (1991) (27)
Acute haemolysis after ABO-incompatible platelet transfusions (1990) (27)
BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations (2009) (26)
Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatment (1998) (26)
Follicular non-Hodgkin's lymphoma. (1987) (25)
Localisation of a novel region of recurrent amplification in follicular lymphoma to an approximately 6.8 Mb region of 13q32-33. (2001) (25)
Staging for Hodgkin's disease. (1979) (25)
Early central nervous system involvement in adults with acute non-myelogenous leukaemia. (1977) (24)
Localized non-Hodgkin's Lymphoma. (1980) (24)
The management of localized, infradiaphragmatic Hodgkin's disease: Experience of a rare clinical presentation at St Bartholomew's Hospital (1984) (24)
The air crescent sign of invasive pulmonary aspergillosis in acute leukaemia. (1982) (24)
The treatment of acute myelogenous leukemia in adults. (1982) (24)
Treatment of acute myelogenous leukemia. (1997) (24)
Human trithorax gene rearrangements in therapy-related acute leukaemia after etoposide treatment. (1994) (23)
Mediastinal large-cell lymphoma with sclerosis (MLCLS). (1994) (23)
Prophylactic granulocyte transfusions: results of a randomized controlled trial in patients with acute myelogenous leukemia (1982) (22)
Computed tomography (CT) and ultrasound (US) guided core biopsy in the management of non-Hodgkin's lymphoma. (1991) (22)
Mutation of BRAF is uncommon in AML FAB type M1 and M2 (2003) (22)
Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: preliminary results of a randomized trial in progress. (1991) (22)
Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis (2012) (22)
Weekly VAPEC-B chemotherapy for high grade non-Hodgkin's lymphoma: results of treatment in 184 patients. (1994) (22)
Immunocytochemical demonstration of PTHrP protein in neoplastic tissue of HTLV-1 positive human adult T cell leukaemia/lymphoma: implications for the mechanism of hypercalcaemia. (1991) (22)
Staging in Hodgkin's disease. (1979) (21)
The t(14;18) chromosomal translocation and Bcl-2 protein expression in Hodgkin's disease. (1994) (21)
Detection of spread of malignant lymphoma to the liver by low field strength magnetic resonance imaging. (1986) (21)
Hepatitis C infection in multitransfused patients with acute leukaemia (1990) (20)
Gonadal function in men treated for acute leukaemia. (1983) (20)
CT appearances of mucosa-associated lymphoid tissue (MALT) lymphoma (1999) (19)
Primary gastrointestinal non-Hodgkin lymphoma: still an unresolved question? (1993) (19)
Fluorescence in situ hybridisation studies to characterise complete and partial monosomy 7 in myeloid disorders (1994) (19)
HODGKIN'S DISEASE OCCURRING DURING ACUTE LEUKÆMIA IN REMISSION (1977) (19)
Duplication of one of the products of the t(8;21) translocation in a patient with refractory anemia with excess blasts in transformation. (1987) (19)
Burkitt's lymphoma in British adults: clinical features and response to chemotherapy. (1977) (19)
Low field strength magnetic resonance imaging of bone marrow in acute leukaemia (1988) (19)
The management of stage II supradiaphragmatic Hodgkin's disease at St. Bartholomew's hospital: A retrospective review of 114 previously untreated patients over 14 years (1984) (19)
A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion (2004) (18)
Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD). (2004) (18)
The management of chronic lymphocytic leukemia at a single centre over a 24‐year period: prognostic factors for survival (1994) (18)
Acute myelogenous leukemia (AML) and diabetes insipidus (DI): Further association with monosomy 7 (1992) (18)
Long‐term outcome of patients surviving for more than ten years following treatment for acute leukaemia (2001) (17)
ALL masquerading as AUL. (1983) (17)
Superior outcomes associated with earlier use: Experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin’s lymphoma (NHL) (2005) (17)
Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. (2000) (17)
Association of HLA-DPB with Hodgkin's disease (1992) (17)
Treatment of low grade non-Hodgkin's lymphomas with fludarabine. (1993) (17)
AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia. (2010) (16)
The role of computed tomography in the detection of intrathoracic lymphoma. (1984) (16)
Safe Method of Collecting Leukaemia Cells from Patients with Acute Leukaemia for Use as Immunotherapy (1974) (16)
Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia (2001) (15)
Molecular characterization of a new recombination of the SIL/TAL‐1 locus in a child with T‐cell acute lymphoblastic leukaemia (2002) (15)
Second primary malignant neoplasms in patients treated for hodgkin's disease at st bartholomew's hospital (1986) (15)
The management of stage 111a hodgkin's disease (1980) (15)
Improved survival for patients with follicular lymphoma. (2005) (15)
E-SHAP: inadequate treatment for poor-prognosis recurrent lymphoma. (1993) (14)
The t(14;18) in a patient with de novo acute lymphoblastic leukemia is associated with t(8;9). (1994) (14)
Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia (1989) (14)
High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma (2004) (14)
Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia. (2002) (14)
Simultaneous presentation of T- and B-cell malignant lymphoma with bcl- 2 gene involvement (1989) (13)
HLA CLASS I AND CLASS II ANTIGEN ASSOCIATIONS IN ACUTE LEUKAEMIAS (1986) (13)
The treatment of acute myelogenous leukemia. (1987) (12)
Molecular cloning of a novel 11q23 breakpoint associated with non-Hodgkin's lymphoma. (1994) (12)
Minimal residual disease in leukaemia and lymphoma. (1990) (12)
EVA treatment for recurrent or unresponsive Hodgkin's disease (2004) (12)
The treatment of postmenopausal women with advanced breast cancer with buserelin (2004) (12)
Incidence of the 15q+;17q- chromosome translocation in acute promyelocytic leukaemia (APL). (1985) (12)
Posttreatment laparotomy as a guide to management in patients with Hodgkin's disease. (1982) (12)
High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia. (2000) (12)
Current management of follicular lymphoma. (1996) (12)
Induction of CD80 expression in low-grade B cell lymphoma--a potential immunotherapeutic target. (1995) (12)
High-dose cytosine arabinoside in the initial treatment of acute leukemia. (1985) (12)
Preliminary results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenström's macroglobulinaemia (2007) (12)
Development of response criteria (rc) for low-grade or follicular lymphomas (lg/f nhl) and application in a 166 patient study (1997) (12)
Neurological illness following treatment with fludarabine. (1994) (11)
The use of high-dose cytosine arabinoside for non-Hodgkin's lymphoma. (1985) (11)
Meningeal leukaemia in lymphoid blast crisis of chronic myeloid leukaemia. (1977) (11)
Neurotoxicity of high-dose cytosine arabinoside. (1985) (11)
Myeloablative therapy for follicular lymphoma. (1991) (11)
Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy (2000) (11)
Proliferation of Reed-Sternberg cells and variants in Hodgkin's disease. (1994) (11)
A comparison of two schedules of cytosine arabinoside used in combination with adriamycin and 6-thioguanine in the treatment of acute myelogenous leukemia. (1982) (11)
Prognostic importance of immunologic markers in adult acute lymphoblastic leukemia. (1981) (11)
Combined granulocyte and platelet transfusions. Development of alloimmunization as reflected by decreasing cell recovery values (1982) (11)
Intensive chemotherapy for adult acute lymphoblastic leukaemia given with or without granulocyte-macrophage colony stimulating factor (1996) (10)
Chronic lymphocytic leukaemia presenting as a blast cell crisis. (1984) (10)
Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours? (2000) (10)
PCR Analysis for the t(14;18) Translocation in Patients With Recurrent Follicular Lymphoma Following Immunotherapy With Rituximab (IDEC-C2B8) (1999) (9)
Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients (1995) (9)
Relationship between Protein Binding and Extravascular drug Concentrations of a Water-soluble Drug, Cytosine Arabinoside 1 (1983) (9)
The Activity of the Novel Aurora Kinase B Inhibitor AZD1152 in Acute Myeloid Leukaemia Cells. (2005) (9)
Autoimmune thrombocytopenia and neutropenia after remission induction therapy for acute leukaemia (1986) (9)
Possible prolongation of remission in acute myeloid leukemia by granulocyte transfusions. (1980) (9)
Central nervous system toxicity of interferon. (1985) (9)
Limited activity of ICRF-159 in advanced acute leukemia. (1979) (9)
Prognostic factors in lymphoma (1987) (9)
Role of additional radiotherapy in advanced stages of Hodgkin's disease. (1992) (8)
15/17 chromosome translocation in acute promyelocytic leukemia. (1982) (8)
High-dose therapy for follicular lymphoma revisited: not if, but when? (2003) (8)
A phase I and II study of m-AMSA in acute leukaemia (2004) (8)
The effect of cytokines on cultured mononuclear cells from patients with B cell chronic lymphocytic leukemia (1993) (7)
Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML) (2004) (7)
THE CHALLENGE OF ACIJTE LYMPHOBLASTIC LEIIKAEMIA IN ADULTS (1993) (7)
Mutation of CEBPA in Familial Acute Myeloid Leukaemia. (2004) (7)
Who should receive myeloablative therapy for lymphoma? (2004) (7)
Subtle abnormalities in the short arm of chromosome 11 in acute myeloid leukemia. (1987) (7)
Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy (1992) (7)
Prognostic significance of cell surface phenotype in adult acute lymphoblastic leukaemia (1979) (7)
Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma. (2000) (7)
The management of follicular lymphoma. (1994) (7)
Interim results of a UK NCRI randomised trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA Hodgkin lymphoma (2007) (7)
In vitro testing of calcium channel blockers and cytotoxic chemotherapy in B-cell low-grade non-Hodgkin's lymphoma. (1998) (6)
Polyradiculopathy complicating acute lymphoblastic leukemia (1995) (6)
Assignment1 of brain acid-soluble protein 1 (BASP1) to human chromosome 5p15.1→p14, differential expression in human cancer cell lines as a result of alterations in gene dosage (2000) (6)
The role of transtracheal aspiration in the diagnosis of respiratory infection in neutropenic patients with acute leukaemia. (1981) (6)
Subcutaneous infusion of cytosine arabinoside (1983) (6)
Sclerosing B-cell lymphoma of the mediastinum: entity or non-entity? (1991) (6)
Iodine-131 Tositumomab For Patients With Small Lymphocytic Lymphoma (SLL): Overall Clinical Trial Experience (2000) (6)
Simultaneous presentation of T- and B-cell malignant lymphoma with bcl-2 gene involvement. (1989) (6)
POLYMERASE CHAIN REACTION TO CONFIRM EXTRANODAL PROGRESSION OF FOLLICULAR LYMPHOMA (1989) (6)
Primary gastric non-Hodgkin's lymphoma: a therapeutic challenge. (1993) (6)
William Dameshek and Frederick Gunz's Leukemia (1990) (6)
Opec chemotherapy (vincristine, prednisolone, etoposide and chlorambucil) for refractory and recurrent Hodgkin's disease (1987) (6)
The treatment of stage IIIA Hodgkin's disease--total nodal irradiation versus combination chemotherapy: either or neither. (1991) (6)
Application of Jackson, Aspden Acute Myeloid Leukaemia Model (1982) (6)
Oral idarubicin as a palliative agent in leukemia (2006) (6)
Low field strength magnetic resonance imaging of the spleen: results from volunteers and patients with lymphoma. (1988) (6)
The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension (2004) (5)
The clinical pharmacology of cytosine arabinoside. (1983) (5)
Assignment1 of B-cell lymphoma 6, member B (zinc finger protein) gene (BCL6B) to human chromosome 17p13.1 by in situ hybridization (2000) (5)
Waldenstrom's macroglobulinemia: a retrospective analysis of 40 patients from 1972 to 2001. (2003) (5)
Conventional dose cytosine arabinoside in combination chemotherapy for acute myelogenous leukemia. (1987) (5)
Recombinant interferon‐ALPHA2b and high dose methyl prednisolone in relapsed and resistant multiple myeloma (1993) (5)
Prognostic factors in adult acute lymphoblastic leukemia. (1979) (5)
T‐cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies (2012) (5)
Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues : Report of the Clinical Advisory Committee Meeting — Airlie House , Virginia , November 1997 By (1999) (5)
SURVIVAL IN ACUTE MYELOID LEUKÆMIA (1975) (5)
Blood component therapy. (1978) (5)
Cytosine arabinoside in the management of recurrent leukaemia (1987) (5)
Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside (2004) (5)
Treatment of acute nonlymphocytic leukemia with neocarzinostatin. (1979) (5)
Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas (2010) (5)
Hairy cell leukemia—mediastinal involvement. A report of two cases and review of the literature (1989) (4)
Infection in acute myelogenous leukaemia. An analysis of 168 patients undergoing remission induction. (1981) (4)
Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin’s Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy. (2004) (4)
Clinical sensitivity to anthracyclines in PH/BCR+ acute lymphoblastic leukemia. (1999) (4)
Patterns of CNS Involvement in Malignant Lymphoma (1979) (4)
Myeloablative therapy with autologous bone marrow transplantation (ABMT) as consolidation of first remission in younger patients with acute myelogenous leukaemia (AML). (1993) (4)
A phase I study of human lymphoblastoid interferon in patients with hematological malignancies. (1981) (4)
Small-cell lung carcinoma: survival after combination chemotherapy, radiotherapy or symptomatic treatment. (1983) (4)
Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion. (1979) (4)
Lack of prognostic value of the thymidine-labelling index in adult acute leukaemia. (1981) (4)
Lymphdx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma. (2004) (4)
Recombinant human granulocyte macrophage colony stimulating factor following alternating non cross resistant chemotherapy in hodgkin's disease (2006) (4)
Multi-centre, phase II study of combination antibody therapy with epratuzumab plus rituximab in relapsed/refractory indolent and aggressive NHL: Promising preliminary results (2004) (4)
Assessment of bone marrow infiltration in B-cell non-Hodgkin's lymphoma (NHL). (1989) (4)
The challenge of acute lymphoblastic leukaemia in adults. (1993) (3)
Interferon in acute myelogenous leukaemia: a preliminary report. (1983) (3)
Malignant lymphoma of the ureter. (1985) (3)
Progress in acute myeologenous leukemia. (1981) (3)
Genome-Wide Micro-Deletions and Amplifications Acquired at Relapse in Acute Myeloid Leukemia. (2009) (3)
Combination chemotherapy for advanced non-Hodgkin's lymphoma of unfavourable histology (2004) (3)
The isolation of a yeast artificial chromosome which spans the chromosome 11q23 region involved in a number of translocations in acute leukaemias. (1993) (3)
Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. (2015) (3)
Short-term therapy for acute myelogenous leukaemia (AML) (1986) (3)
The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab. (2005) (3)
The proposed revised European-American classification of lymphoma. (1995) (3)
Effect of ceftazidime and gentamicin on the oropharyngeal and faecal flora of patients with haematological malignancies. (1990) (3)
Mantle Cell and Follicular Lymphoma Samples Demonstrate Differing Sensitivity to Bortezomib in a Primary Culture System. (2004) (3)
Combined granulocyte and platelet transfusions: inter-relationship between granulocyte and platelet recoveries in the presence and absence of complicating factors. (2009) (3)
Staging for hodgkins-disease. (1990) (3)
THE STAGING AND TREATMENT OF NON‐HODGKIN'S LYMPHOMA (1978) (3)
WHO SHOULD TREAT CANCER? (1981) (3)
Follicular lymphoma: grounds for optimism. (1997) (3)
Detection of somatic mutations of the bcl-2 oncogene in B cell lymphomas with the t(14;18). (1997) (2)
Treatment of minimal residual disease in poor risk acute lymphoblastic leukaemia with high-dose cytosine arabinoside (ARA-C) (1986) (2)
Late complications of cytotoxic chemotherapy given for advanced Hodgkin’s disease (1985) (2)
Acute Myelogenous Leukaemia in Patients 60 Years and Older: A Retrospective Analysis from St Bartholomew's Hospital 1969–1999 (2001) (2)
Genome Wide SNP Analysis Reveals Frequent Uniparental Disomy (UPD) Due to Somatic Recombination in Acute Myeloid Leukemias. (2004) (2)
Multi-centre, phase II study of combination antibody therapy with epratuzumab plus rituximab in relapsed/refractory indolent and aggressive NHL: Promising preliminary results. (2004) (2)
Phase II study of a high-dose regimen of cyclophosphamide and prednisolone in advanced non-Hodgkin's lymphoma of favorable histologic type. (1982) (2)
p53 protein expression in Reed-Sternberg cells of Hodgkin's disease. (1993) (2)
Can the polymerase chain reaction be used to direct therapy? (1993) (2)
Management of stage II Hodgkin's disease: 15 years experience at St. Bartholomew's Hospital. (1992) (2)
Chemotherapy of Hodgkin's disease. (1991) (2)
Molecular Diagnosis of Lymphoma (2005) (2)
Role of anthracycline dose intensity in adult Philadelphia chromosome/BCR-ABL positive and negative B-lineage acute lymphoblastic leukemia (1999) (2)
Comparison of Clinical Trials in Acute Myelogenous Leukaemia by use of a Mathematical Model (1980) (2)
The ‘tumour overkill syndrome’. A potentially lethal complication of cancer chemotherapy (1981) (2)
Management of non-Hodgkin lymphoma in adults in Scandinavia, United Kingdom, and The Netherlands. Report from the European School of Oncology intercity meeting at Huddinge Hospital, 3rd June, 1988. (1989) (2)
Treatment of Stage IIIa Hodgkin's disease: long follow-up perspective. (2008) (2)
A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults (2004) (2)
The lymphomas--current management. (1983) (2)
Hodgkin's disease occurring during acute leukaemia in remission. (1977) (2)
VAPEC B: a weekly chemotherapy for high grade non-Hodgkin's lymphoma. Early results of a collaborative trial at two centres. (1990) (1)
Enteropathy-Type T-Cell Lymphoma: Clinical Features of a Series of 62 Cases. Jan Delabie, Harald Holte, Andrew Lister and Julie Vose for the International T-Cell Lymphoma Project. (2006) (1)
The Relationship of Cell Morphology to CNS Involvement in Adult Leukaemia and Lymphoma (1979) (1)
Patterns of relapse and subsequent management following high dose chemotherapy with autologous haemopoietic support in relapsed or refractory Hodgkin's lymphoma (2000) (1)
Limited Success with a Postremission Strategy Comprising Conventional Consolidation and High-Dose Treatment (HDT) with Autologous Peripheral Progenitor Cell (PBPC) Support for Adult Acute Lymphoblastic Leukaemia (ALL) (2003) (1)
Evaluation of emotional support for cancer patients (1997) (1)
Acute promyelocytic leukaemia: a retrospective analysis of patients treated at St. Bartholomew's Hospital 1969–1995 (1999) (1)
The management of stage IIIA Hodgkin's disease. (1980) (1)
High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: A study (2005) (1)
Chronic Lymphocytic Leukemia (2003) (1)
The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology (2004) (1)
Generation of cytotoxic T lymphocytes from peripheral blood of leukaemic patients (2005) (1)
Treatment of recurrent acute myelogenous leukaemia at a single centre over a 10-year period. (1990) (1)
Acute myelogenous leukemia with dup(1)(p22p36),dup(1)(p22p36): a novel case? (1996) (1)
Triple drug therapy of Herpes zoster infection occurring in patients with reticulo-endothelial neoplasia--a preliminary study. (1980) (1)
Pivotal S tudy o f I odine I 1 31 T ositumomab f or Chemotherapy-Ref ractory L ow-Grade o r T ransformed Low-Grade B -Cell N on-Hodgkin's L ymphomas (2001) (0)
Chronic lymphocytic leukaemia. (1991) (0)
splenic artery infusion Treatment of refractory splenomegaly in myeloproliferative disease by (2012) (0)
The Wiskott-Aldrich-Syndrome family member 1 (WASF1) gene on 6q21 is down-regulated in specific AML cytogenetic subtypes. (2003) (0)
772 Multicentre retrospective review of primary cutaneous lymphoma excluding mycosis fungoides (1995) (0)
Levels of Evidence of Carcinogenicity (1993) (0)
CT guided biopsy in the management of non-Hodgkin's lymphoma. (1990) (0)
Presenting features of lymphoid neoplasms : S MONTOTO AND TA LISTER (2010) (0)
Outcome of Patients with Refractory/Recurrent Acute Myelogenous Leukaemia (AML) Treated at a Single Centre (2003) (0)
Historical prospect for the concept of primary extranodal lymphoma (2008) (0)
Lowfield strength magnetic resonanceimaging ofthespleen: results from volunteers andpatients withlymphoma (1988) (0)
Simultaneous presentation of B- and T-cell malignant lymphoma. (1989) (0)
Monoclonal Antibodies for Cancer Detection (1986) (0)
Resistance to Cytosine Arabinoside: Are Mutations in CTP Synthetase an Important Mechanism? (1994) (0)
The management of generalised lymphoma. (1975) (0)
Third Annual Meeting of the Association of Cancer Physicians (in Conjunction with the 29th Annual General Meeting of the British Association for Cancer Research)* (1988) (0)
Gene Expression Model of Survival and Transformation in Follicular Lymphoma (FL): A Study by the LLMPP. (2007) (0)
The Management of Follicular Lymphoma (2012) (0)
Outcome after high-dose therapy with autologous stem cell rescue with BEAM for relapsed follicular lymphoma. (2011) (0)
relapsed acute myeloid leukemia Segmental uniparental disomy is a commonly acquired genetic event in (2013) (0)
Contents Vol. 89, 2000 (2000) (0)
H.I.V. antibody testing in lymphoma patients. (1987) (0)
Genome-Wide 500K SNP Array Analyses Reveal High Frequencies of Cryptic Genetic Abnormalities and Identify Recurrent Microdeletions Targeting Novel Genes in Adult Acute Lymphoblastic Leukemia. (2007) (0)
Early Application of Anthracyclines in Adult Acute Lymphoblastic Leukemia (ALL) (2001) (0)
Short-term therapy for acute myelogenous leukaemia in younger patients. (1983) (0)
Response to Fludarabine in Patients with Low Grade Lymphoma (1996) (0)
DNA sequence determination of CTP synthetase mutations in ara C-resistant hamster cells. (1991) (0)
In vitro treatment of bone marrow from patients with T-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma using the immunotoxin WT1-ricin A. (1987) (0)
Treatment of Disseminated Malignant Lymphoma (1984) (0)
17 Fluorodeoxyglucose (FDG) positron emission tomography (PET) in Lymphoma (2010) (0)
Myelo-ablative therapy with ABMT for low grade non-Hodgkin's lymphoma (1995) (0)
Diagnosis and management of pulmonary aspergillosis in patients with acute leukaemia (1980) (0)
Letter: Survival in acute myeloid leukaemia. (1975) (0)
The feasibility of opal/high dose Ara-C treatment of adult acute lymphoblastic leukaemia. (1985) (0)
The role of image-guided biopsy in the management of patients with lymphoma (1996) (0)
IN13 Follicular lymphoma (2012) (0)
Management of elderly patients with 'aggressive' non-hodgkin's lymphoma (NHL) presenting to a single centre over three decades (2002) (0)
Letter to the editor (1987) (0)
Fludarabine in chronic lymphocytic leukaemia and non-Hodgkin's lymphoma. 5th Annual Meeting, Association of Cancer Physicians, March 1990. (1990) (0)
Intensive combination chemotherapy for diffuse low grade non-Hodgkin's lymphomas of B- and T-cell lineage. (1993) (0)
Subject Index Vol. 89, 2000 (2000) (0)
THE ROLE OF COMPUTER TOMOGRAPHY IN THE DETECTION OF INTRATHORACIC LYMPHOMA (1985) (0)
Combination chemotherapy foracutelymphoblastic leukaemia inadults (1978) (0)
REVIEWARTICLES Thelymphomas-current management (1983) (0)
Association of MicroRNA Expression Profiles with Karyotype in Acute Myeloid Leukaemias Revealed by Real-Time PCR and In Situ Hybridisation. (2007) (0)
Diagnosis and staging or Hodgkin s disease (1990) (0)
High-Dose Cytosine Arabinoside in the Treatment of Acute Lymphoblastic Leukaemia (1994) (0)
Intermediate dose cytosine arabinoside and etoposide for the treatment of refractory or relapsed acute leukaemia and non-Hodgkin's lymphoma. (1991) (0)
Clinical interferon (IFN) studies in leukemia and lymphoma (1985) (0)
AML 1 / ETO Proteins Control POU 4 F 1 / BRN 3 A Expression and Function in t ( 8 ; 21 ) Acute Myeloid Leukemia (2010) (0)
‘ ‘ focus on . . . ’ ’ session : transformation 086 SNP ARRAY GENOTYPING IN 182 DIAGNOSTIC FOLLICULAR LYMPHOMA CASES IDENTIFIES SITES OF AUPD ASSOCIATED WITH OVERALL SURVIVAL AND RISK OF TRANSFORMATION (2008) (0)
Development of a Human Acute Myeloid Leukaemia Screening Panel and Identification of Novel Gene Mutations. (2004) (0)
Cytosine arabinoside: pharmacokinetics following different routes of administration (1982) (0)
Prognostic Factors in Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia (2001) (0)
Unusual myeloid leukaemia in patient with Hodgkin's disease. (1987) (0)
‘ ‘ focus on . . . ’ ’ session : profiling and prognosis (2008) (0)
evaluation ofa novelpredominantly lymphocyte selective agentinlymphoid malignancies (1993) (0)
Total Histology Nodular sclerosis Lymphocyte predominant Mixed cellularity Lymphocyte deplete Unspecified Stage II Ill IV B symptoms Outcome Complete remission Complete remission (0)
Lowfield strength magnetic resonanceimaging ofbonemarrowin patients withmalignant lymphoma (1988) (0)
Fludarabine in Low-Grade Lymphoma: st. Bartholomew's Hospital Experience (1997) (0)
Wilm’s Tumour 1 (WT1) Mutations Are Associated with FLT3-ITD Mutation and Poor Prognosis in Normal Karyotype AML. (2006) (0)
Follow-Up Results of a Prospective, Multicenter, Open-Label Study of Oral Fludarabine Phosphate in Patients with Previously Untreated B-CLL. (2005) (0)
The treatment of low grade non-Hodgkin's lymphoma in elderly people. (1993) (0)
Cotswolds Modification of the Ann Arbor Staging System for Hodgkin's Disease (1990) (0)
More about: B-cell non-Hodgkin's lymphoma: evidence for the t(14;18) translocation in all hematopoietic cell lineages. (1999) (0)
Gonadal Function in Hodgkin’s Disease: Long-Term Follow-Up of Chemotherapy (1983) (0)
Chronic Lymphocytic Leukemia: Diagnosis and Management (2002) (0)
Serum selenium in lymphoma - In reply (2004) (0)
Diagnosis and Management (2020) (0)
Letters to the editor (0)
Presenting features of lymphoid neoplasms (2010) (0)
Short Term Chemotherapy for Acute Myelogenous Leukaemia (1984) (0)
Phase I Trial of the 131I-Labelled Anti-CD25 Antibody Basiliximab in the Treatment of Patients with Relapsed or Refractory Lymphoma. (2007) (0)
Report o f a n I nternational W orkshop t o S tandardize Response C riteria f or N on-Hodgkin's L ymphomas (1999) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With T. Andrew Lister?

T. Andrew Lister is affiliated with the following schools:

T. Andrew Lister's Academic­Influence.com Rankings

T. Andrew Lister's Degrees

Why Is T. Andrew Lister Influential?

T. Andrew Lister's Published Works

Published Works

What Schools Are Affiliated With T. Andrew Lister?

T. Andrew Lister's AcademicInfluence.com Rankings